Agenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus’ Anti-TIGIT Bispe...

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Agenus executives will conduct a conference call to discuss the global licensing agreement between Agenus and Bristol Myers Squibb at 8:30 a.m. ET today.

Conference CallDial-in numbers: [phone] (US) or [phone] (International); Conference ID: 6545558.

WebcastA live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/gmikyrev.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

ContactAgenus Investor RelationsJan Medina, [e-mail]

Agenus Media RelationsKimberly HaKKH [e-mail]